rHb1 data

SMTG (Boulder, Colo.) reported preliminary Phase I/II data showing the ability of the recombinant molecule to stay together in the body, avoiding toxic effects of the dissociated dimers on the kidneys.

Eighteen patients undergoing orthopedic surgery received escalating doses of the agent in a single-blind trial, as a 5 percent solution infused at 3-4 mL/kg/hr. The largest dose was 25.6 g. Four patients received saline. ...